Symcel partners with Karolinska Institutet to validate calScreener in clinical antimicrobial susceptibility testing.

The collaboration will evaluate Symcel’s cell-based assay tool, calScreener, designed to measure cell metabolism in real-time.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The technology will be assessed for its ability to test the efficacy of different antibiotic combinations against drug-resistant bacteria in sepsis patients.

Karolinska University Hospital associate professor Christian Giske will lead the research that aims to validate calScreener as a ‘reliable reference point’ for clinical microbiologists.

Giske said: “Early results from our initial tests on Symcel’s technology, carried out in our research laboratories, showed that calScreener has great promise for use in clinical laboratories and for addressing key challenges in antimicrobial susceptibility testing.”

According to Symcel, The calScreener method is well positioned for combination testing due to its total metabolic response in real-time, very high sensitivity and no limit to the number of antimicrobials that can be tested at once.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“calScreener can aid antimicrobial stewardship as the ability to generate actual results and data on antimicrobial resistance at an early stage enables informed judgments to be made in good time.”

It can optimise monotherapies to prevent the use of sub-efficient concentrations of a compound and offers an alternative to the standard reference methods that are often slow and not suitable for multi-resistant bacteria.

Symcel CEO Jesper Ericsson said: “calScreener can aid antimicrobial stewardship as the ability to generate actual results and data on antimicrobial resistance at an early stage enables informed judgments to be made in good time on whether to switch or modify a treatment.

“We are confident that our technology will emerge as a validated and unique surrogate method that will enable clinicians to correctly determine which antibiotics really work against multi-resistant bacteria.”